Marty Makary
speaker
939 appearances
6 recordings
5 series
first heard Jan 2026
last heard 13 May
Marty Makary’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 6 in all, peaking in Jan 2026 with 4.
Appearances
And are there priorities that you're working with Congress on to try and accelerate drug approval timelines that are necessary?
And going back to this point about cutting down on timelines for phase one, two, three, maybe you can just for the audience that may not work in this industry, very briefly explain phase one, two, three, and then where we think there's the biggest kind of, call it excess regulatory burden that's causing these extended timelines on drug approvals, just to kind of frame it up a little bit.
You're making me sick, because this has always been, from my point of view, one of the most troubling bioethical concerns I've had about the industry, because you don't get a lot of statistical power or benefit from doing this, and it's just awful that we do it.
And if we don't, then we're also putting our industry at risk.
So the drug company gets a voucher if they qualify under one of those three criteria and that gives them a fast track?
Yeah.
And when will we get a readout on how that program is going and whether it becomes standard?
Going back to the computational point, we are collecting more data, digitizing that data on patients than ever before.
That data should generally be accessible.
Is there a world where we can transition from phase one, phase two, phase three trials
into a phase one, phase two slash three by taking into account all of this additional data.
Some people have talked about the idea of using AI plus other health data that's collected and allowing the phase three to kind of roll into phase two and create a much more expedited computationally assisted approval process.
Is that something that's on the roadmap or is discussed?
And is there more continuous tracking that's also possible to look for risks and issues that start to emerge in certain populations?
Because this is something that it's almost like the approval happens and then
you find out years later that, well, maybe there was an issue that we should have caught sooner.
And if you move to a more data-driven, continuous observational system, can you both have faster approvals, but also faster recognition of safety concerns for specific populations?
For people in the general audience to understand, this begs the question, and I think people will bring this up as a critique, of absolute safety.
I always talk about the example of you put the Waymos or the autonomous cars on the road,
They cut down on fatalities by 95%.
Showing 421–440 of 939 · page 22 of 47
← Previous
Next →